

Special Issue

Cancer Immune Escape and Immunotherapy

Message from the Guest Editors

More and more evidence is delineating an articulated picture of the complex balance in tumor immune-editing that can protect the host against tumor development or promote tumor escape. In different clinical trials, antibody targeting of immune checkpoints mainly expressed by T and NK lymphocytes has presented the possibility to activate the immune system to achieve tumor controls. However, this approach can be limited by the onset of immune-related adverse effects and needs to be combined with other anti-tumor therapies to convert non-responders to responders. Cellular immunotherapy and neoantigen-based vaccines could represent efficient alternatives to develop precision immune-oncology. In this Special Issue, we encourage authors to present recent advances in immunotherapy strategies against hematological and non-hematological tumors as well as new insights into the particular composition of the solid tumor microenvironment that, with its immunosuppressive cytokines and enzyme products; altered nutrients availability; and, in some cases, mesenchymal and collagen barrier molecules, represents a strong limitation to the tumor eradicating function of T and NK cells.

Guest Editors

Dr. Simona Carlomagno

Department of Experimental Medicine, University of Genoa, 16126 Genova, Italy

Prof. Dr. Mariella Della Chiesa

Department of Experimental Medicine, University of Genoa, 16126 Genova, Italy

Deadline for manuscript submissions

closed (30 April 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/83985

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).